Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

eatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation our expectation regarding continued growth of Esbriet revenues in Germany, other EU countries and Canada, our anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in Canada, France, Italy, Spain, the United Kingdom and other EU countries, the estimated size of the patient population in Canada suffering from IPF and our expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof, our expectations regarding headcount in our Canadian commercial organization and the functions of such personnel, and our expectation regarding the timing and nature of full enrollment in, and results of, the ASCEND study and the prospects of success thereof.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune ass
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune To Release Third Quarter Financial Results On November 7
2. InterMune To Present At JMP Securities Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune to Present at J. P. Morgan Healthcare Conference
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
8. Patient Safety Technologies Reports Third Quarter 2012 Results
9. PDI Reports 2012 Third Quarter Financial Results
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... be allowed to tax Internet usage, in a move that ... hole in the state budget. , ,The federal measure to ... , R-Wis., who said home users could save around a ... Tax Nondiscrimination Act, a tech-neutral plan that exempts all Internet ...
... Dark Ages, where marks were burned onto cattle. On ever-so-slowly-evolving minds ... solid impression and provides a daily dose of comfort. Belonging to ... a security blanket. A warm fuzzy feeling when a huge name ... craves to carry something with a logo, color and stripes, wear ...
... Wis. The North Carolina simulated learning company ... the Croquet Project at UW-Madison, a graphical communications ... trade show in Orlando that it has begun developing software ... applied to military and commercial avenues. , ,What were doing ...
Cached Biology Technology:State faces revenue drop as federal Internet tax ban passes House 2The black hole of corporate branding 2The black hole of corporate branding 3The black hole of corporate branding 4UW open-source 3D environment tapped for commercial development 2
(Date:8/20/2014)... therapy developed by researchers at the University of Missouri ... from a life-threatening heart condition caused by muscular dystrophy. ... Yi Lai, Ph.D., the leading author of the study ... Medicine,s Department of Molecular Microbiology and Immunology. "This is ... lead to a treatment for people with this devastating ...
(Date:8/20/2014)... 1 (PS1) absorbs light and its energy is ... to biomass. Photovoltaic devices, mostly build from silicon ... electricity. One approach for the development of cheaper ... with the isolated membrane protein complexes of photosynthesis. ... stable PS1 from thermophilic cyanobacteria that live in ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... urine test for prostate cancer that measures minute fragments ... through the University of Michigan MLabs. The new testMi-Prostate ... increases physicians, ability to pick out high-risk prostate tumors ... of thousands of men avoid unnecessary biopsies. The ...
... 2013 MedNet Solutions , a global life ... is pleased to announce that Accelovance , an ... phase Oncology, Vaccines and General Medicine development, has joined ... .    Designation as an iMedNet Partner will ...
... the first ever interior 3D map of Italy,s iconic Leaning ... system. Developed by the CSIRO, Australia,s national science agency, ... a laser scanner that sways on a spring to capture ... an operator can walk through it. Specialised software then converts ...
Cached Biology News:Prostate Cancer Foundation announces new urine test for prostate cancer available 2Prostate Cancer Foundation announces new urine test for prostate cancer available 3MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 33D mapping is a 'Pisa' cake for Aussie scientists 2
... software, PC, is used to perform ... obtained from the Experion automated electrophoresis ... electropherogram and simulated gel views and ... in a Results table. This software ...
... use in the Microsart e.motion are sterile-sealed, without ... a specially designed individual package on a band. ... of membrane filter units ensures that they are ... sealed band guarantees uniform dispensing of the individual ...
... that will help protect your PCR runs ... work area prior to use, reducing the ... Containment features reduce the chance of airborne ... for a clear view, an acid-resistant black ...
...
Biology Products: